Spironolactone as an Adjunctive Treatment in Neovascular Age-Related Macular Degeneration
Neovascular age-related macular degeneration (AMD) is a potentially sight-threatening condition. The current standard-of-care treatment regimen is serial intravitreal antivascular endothelial growth factor injections. While these typically have great success, they do carry exceptional treatment burd...
Main Authors: | Kapil G. Kapoor, Jennifer Sim |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2017-05-01
|
Series: | Case Reports in Ophthalmology |
Subjects: | |
Online Access: | http://www.karger.com/Article/FullText/475880 |
Similar Items
-
Mineralocorticoid Receptor Antagonists Eplerenone and Spironolactone Modify Adrenal Cortex Morphology and Physiology
by: Sofia S. Pereira, et al.
Published: (2021-04-01) -
Possible role of Spironolactone in a sample of Iraqi patients with acute central serous chorioretinopathy
by: Marwa Majeed Hameed, et al.
Published: (2022-05-01) -
Clinical feature of cystoid macular degeneration in central serous chorioretinopathy
by: Sukanya Gorhe, et al.
Published: (2023-01-01) -
Oral eplerenone for the management of chronic central serous chorioretinopathy
by: Rishi P Singh, et al.
Published: (2015-04-01) -
Visual and anatomical outcomes of spironolactone therapy in patients with chronic central serous chorioretinopathy
by: Khalil Ghasemi Falavarjani, et al.
Published: (2017-01-01)